Trade BMEA anytime, even after market hours
Regulated by
MAS
Trusted by
400,000+ users
Biomea Fusion, Inc. (BMEA) is trading at US$2.03, up 6.28% today as of Sep 4, 16:00 EDT. The company has a market capitalisation of US$99.3M. Over the past 52 weeks, BMEA has traded between US$0.87 and US$2.99. On Syfe you can trade BMEA with $0 commission and add it to your watchlist.
| Previous close | US$1.91 |
|---|---|
| Market cap | US$99.3M |
| 52-week range | US$0.87 – US$2.99 |
| Volume | 3.27M |
| Exchange | US |
Add to Watchlist
Set Price Alert
Biomea Fusion, Inc.
Biomea Fusion, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic disorders, such as diabetes. It offers its lead product candidate, BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. The company was founded by Thomas Butler and Ramses Erdtmann in August 2017 and is headquartered in San Carlos, CA.
Year: 2021
Biomea Fusion, Inc. (BMEA) stock is trading at US$2.03, +6.28% from the previous close of US$1.91.
The market cap for Biomea Fusion, Inc. (BMEA) stock is approximately US$99.3M.
The 52-week high for Biomea Fusion, Inc. (BMEA) stock is US$2.99.
The 52-week low for Biomea Fusion, Inc. (BMEA) stock is US$0.87.
Biomea Fusion, Inc. (BMEA) does not currently pay a dividend.
Stay on top of BMEA
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
